IQVIA raises 2026 guidance after record quarter and 15% bookings growth

IQVIA raised its full-year 2026 guidance after reporting record third-quarter results, with clinical research bookings posting their strongest quarter since 2022.

Revenue rose 8.0% to $4.428 billion, or 8.6% at constant currency, according to the earnings release attached to its 8-K on Tuesday. Adjusted diluted EPS increased 11.3% to $3.34, and GAAP diluted EPS was $2.10 on net income of $350 million. Adjusted EBITDA rose 8.7% to $1.032 billion.

"IQVIA delivered another record quarter, with revenue, Adjusted EBITDA and Adjusted Diluted EPS all exceeding the high end of our expectations," Chairman and CEO Ari Bousbib said. He said funding, requests for proposals, trial starts and FDA approvals were "all favorable."

Segments

Research & Development Solutions revenue grew 8.7% to $2.639 billion, and net new bookings rose 15% to $3.2 billion. Commercial Solutions revenue increased 6.9% to $1.789 billion.

Bousbib said the company has deployed more than 400 AI agents to date.

Operating cash flow was $825 million and free cash flow was $667 million, representing 120% of adjusted net income.

Guidance raised

IQVIA now expects 2026 revenue of $17.35 billion to $17.5 billion, adjusted EBITDA of $4.025 billion to $4.055 billion and adjusted diluted EPS of $12.90 to $13.00. The revenue outlook includes about 250 basis points of contribution from acquisitions, including deals it expects to complete by year-end, and about 20 basis points of currency tailwind.

The company will hold an investor day on Dec. 1, 2026.

By the numbers

• Q3 revenue: $4.428 billion, up 8.0%
• Adjusted EPS: $3.34, up 11.3%
• R&D Solutions net new bookings: $3.2 billion, up 15%
• Free cash flow: $667 million
• 2026 adjusted EPS guidance: $12.90 to $13.00

Sources

1. IQVIA HOLDINGS INC., Form 8-K with third quarter 2026 earnings release, filed Oct. 27, 2026 (accession 0001628280-26-067406)

This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.

Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.